Network members are actively engaged in both clinical and translational research into children’s allergies and anaphylaxis, as well as new methods of teaching. A number of members are affiliated with Universities in the North West of England, particularly the University of Manchester.

Self-funding students wishing to embark on post-graduate degrees (MD or PhD) with Network members are invited to contact the Network Administrator attaching their up to date CV.

Network Publications

Sinnott L, Dudley-Southern R. Developing allergy services in the North West of England. Lessons Learnt. North West Allergy and Clinical Immunology Network.NWACIN Allergy Report_final





Greenhawt M et al. Updating guidance regarding the risk of allergic reactions to COVID-19 vaccines and recommended evaluation and management: A GRADE assessment and international consensus approach. JACI 2023;152:309-325.
Doan S, et al. Vernal keratoconjunctivitis and clinical evidence and the potential role of omalizumab. World Allergy Organ J 2023;16:100788.
Sharma V, et al. Reporting anaphylaxis deaths to UK fatal anaphylaxis registry. BMJ 2023;381:1195.
Greenhawt M et al. Phase 3 trial of epicutanteous immunotherapy in toddlers with peanut allergy. N Engl J Med 2023;388:1755-1766.
Arkwright PD, Koplin JJ. Challenging best practice of atopic dermatitis. J Allergy Clin Immunol Pract 2023;11:1391-1393


Aoun T, Borrow R, Arkwright PD. Immunogenicity and safety of season influenza vaccines in children under 3 years of age. Exp Rev Vaccines 2023;22:226-242.
Yong PFK et al. A national survey of hereditary angioedema and acquired C1 inhibitor deficiency in the United Kingdom. J Allergy Clin Immunol Pract 2023;11:2476-2484.


Paller AS, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo controlled, phase 3 trial national survey of hereditary angioedema and acquired C1 inhibitor deficiency in the United Kingdom. Lancet 2022;400:908-919.
Arkwright PD, Koplin JJ. Striving for evidence-based management of food allergies. JACI Pract 2022;10:56.58.
Anagnostou A, Sharma V, Herbert L, Turner PJ. Fatal food anaphylaxis: Distinguishing fact from fiction. JACI Pract 2022;10:11-17.
Fernandez-Rivas M, et al. Open-label follow-on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy. Allergy 2022;77:991-1003.
Egg D, et al. Therapeutic options for CTLA-4 insufficiency. J Allergy Clin Immunol 2022;149:736-746..


Paller AS, Wollenberg A, Siegfried E, Thaci D, Cork MJ, Arkwright PD, Gooderham M, Sun X, O'Malley JT, Khokhar FA, Vakil J, Bansal A, Rosner K, Shumel B, Levit NA. Laboratory safety of dupilumab in patients aged 6-11 years with severe atopic dermatitis: results from a phase III clinical trial. Pediatric Drugs 2021;23:515-527.
Arkwright PD, Walter JE. Introducing a new epoch in inborn errors of immunity. J Allergy Clin Immunol Pract 2021;9:660-662.
Fernandez-Rivas M, Vereda A, Vickery BP, Sharma V, Nilsson C, Muraro A, Hourihane JO, DunnGalvin A, du Toit G, Blumchen K, Beyer K, Smith A, Ryan R, Adelman DC, Jones SM.. Open-lab follow-on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy. Allergy 2021;Jul 28.
Sharma V, Garcez T, Fox AT.. Fatal anaphylaxis: making sure all cases are counted. BMJ 2021;Mar 15;372:n691.


Tse HN, Borrow R, Arkwright PD. immune response and safety of viral vaccines in children with autoimmune diseases on immune modulatory drug therapy. Expert Rev Vaccines 2020;19:1115-1127.
Sharma V, Jobrack J, Cerenzia W, Tilles S, Ryan R, Sih-Meynier R, Zeitler S, Manning M. A study to assess current approaches of allergists in European countries diagnosing and managing children and adolescents with peanut allergy. PLoS One 2021;15:e0241648.
Matsuda K, Arkwright PD, Mori Y, Oikawa MA, Muko R, Tanaka A, Matsuda H. A rapid shift from chronic hyperoxia to normoxia induces systemic anaphylaxis via transient receptor potential ankyrin 1 channels on mast cells. J Immunol 2020;205:2959-2967.
Robey RC, Wilcock A, Bonin H, Beaman G, Myers B, Grattan C, Briggs TA, Arkwright PD. Hereditary alpha-tryptasemia: UK prevalence and variability in disease expression. J Allergy Clin Immunol Pract 2020;8:3549-3556.
Paller AS, Siegfried EC, Thaçi D, Wollenberg A, Cork MJ, Arkwright PD, Gooderham M, Beck LA, Boguniewicz M, Sher L, Weisman J, O'Malley JT, Patel N, Hardin M, Graham NMH, Ruddy M, Sun X, Davis JD, Kamal MA, Khokhar FA, Weinreich DM, Yancopoulos GD, Beazley B, Bansal A, Shumel B. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol 2020:85:1282-1293.
O'B Hourihane J, Beyer K, Abbas A, Fernández-Rivas M, Turner PJ, Blumchen K, Nilsson C, Ibáñez MD, Deschildre A, Muraro A, Sharma V, Erlewyn-Lajeunesse M, Zubeldia JM, De Blay F, Sauvage CD, Byrne A, Chapman J, Boralevi F, DunnGalvin A, O'Neill C, Norval D, Vereda A, Skeel B, Adelman DC, du Toit G. Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-bind, randomised, placebo-controlled phase 3 trial. Lancet Child Adolesc Health 2020 Oct;4(10):728-739.
Al Kindi A, Williams H, Matsuda K, Alkahtani AM, Saville C, Bennett H, Alshammari Y, Tan SY, O'Neill C, Tanaka A, Matsuda H, Arkwright PD, Pennock JL. Staphylococcus aureus second immunoglobulin-binding protein drives atopic dermatitis via IL-33. J Allergy Clin Immunol 2020;Oct 1:S0091-6749(20)31335.
Cork MJ, Thaçi D, Eichenfield LF, Arkwright PD, Sun X, Chen Z, Akinlade B, Boklage S, Guillemin I, Kosloski MP, Kamal MA, O'Malley JT, Patel N, Graham NMH, Bansal A. Dupilumab provides favourable long-term safety in chidlren aged >6 to <12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-Label extension study. Br J Dermol 2020 Sep 24.
Akdis CA, Arkwright PD, Brüggen MC, Busse W, Gadina M, Guttman-Yassky E, Kabashima K, Mitamura Y, Vian L, Wu J, Palomares O. Type 2 immunity in the skin and lungs. Allergy 2020;75:1582-1605.
Vuillermin PJ, O'Hely M, Collier F, Allen KJ, Tang MLK, Harrison LC, Carlin JB, Saffery R, Ranganathan S, Sly PD, Gray L, Molloy J, Pezic A, Conlon M, Topping D, Nelson K, Mackay CR, Macia L, Koplin J, Dawson SL, Moreno-Betancur M, Ponsonby AL; J. Craig Venter Institute; BIS Investigator Group. Maternal carriage of Prevotella during pregnancy associates with protection against food allergy in offspring. Nat Commun 2020;11:1452.
Hiscock H, Perera P, Danchin MH, Sung V, Lee K, Stival C, Peat R, Molloy J, Selvakumaran S, Tang MLK. Improving timely access to food allergy care: A pragmatic controlled trial. Allergy 2020;75:1449-1453.
Hiscock Molloy J, Collier F, Saffery R, Allen KJ, Koplin JJ, Louise Ponsonby A, Tang MLK, Ward AC, Martino D, Burgner D, Carlin JB, Ranganathan S, Symeonedies C, Dwyer T; BIS Investigator Group, Vuillermin P. Folate levels in pregnancy and offspring food allergy and eczema. Pediatr Allergy Immunol 2020;31:38-46.
Proctor T, Morrough E, Fenske O, Allatt S, Hughes SM, Sharma V, Arkwright PD. Impact on quality of life and safety of sublingual and subcutaneous immunotherapy in children with severe house dust mite and pollen-associated allergic rhinoconjunctivitis. Clin Transl Allergy 2020;Apr 20:10:10.
Arkwright PD, Mughal MZ. Vertebral, pelvic, and hip fracture risk in adults with severe atopic dermatitis. J Allergy Clin Immunol 2020;145:487-488.
Engelhardt KR, Gertz ME, Keles S, Schäffer AA, Sigmund EC, Glocker C, Saghafi S, Pourpak Z, Ceja R, Sassi A, Graham LE, Massaad MJ, Mellouli F, Ben-Mustapha I, Khemiri M, Kilic SS, Etzioni A, Freeman AF, Thiel J, Schulze I, Al-Herz W, Metin A, Sanal Ö, Tezcan I, Yeganeh M, Niehues T, Dueckers G, Weinspach S, Patiroglu T, Unal E, Dasouki M, Yilmaz M, Genel F, Aytekin C, Kutukculer N, Somer A, Kilic M, Reisli I, Camcioglu Y, Gennery AR, Cant AJ, Jones A, Gaspar BH, Arkwright PD, Pietrogrande MC, Baz Z, Al-Tamemi S, Lougaris V, Lefranc G, Megarbane A, Boutros J, Galal N, Bejaoui M, Barbouche MR, Geha RS, Chatila TA, Grimbacher B. The extended clinical phenotype of 64 patients with dedicator of cytokinesis 8 deficiency. J Allergy Clin Immunol 2015;136:402-12.
Denaxa D, Arkwright PD. Fennel as a cause of immediate hypersensitivity to toothpaste. Ann Allergy Asthma Immunol 2020:125:99-100.
Turner PJ, Gowland MH, Sharma V, Lerodiakonou D, Harper N, Garcez T, Pumphrey R, Boyle RJ. Increase in anaphylaxis-related hospitalizations but no increase in fatalities: an analysis of United Kingdom national anaphylaxis data, 1992-2012. J Allergy Clin Immunol 2015;135:956-63.


Leonardi A, Silva D, Perez Formigo D, Bozkurt B, Sharma V, Allegri P, Rondon C, Calder V, Ryan D, Kowalski ML, Delgado L, Doan S, Fauquert JL. Management of ocular allergy. Allergy 2019;74:1611-1630.
Wilcock A, Bahri R, Bulfone-Paus S, Arkwright PD. Mast cell disorders: From infancy to maturity. Allergy 2019;74:53-63.
Dorjbal B, Stinson JR, Ma CA, Weinreich MA, Miraghazadeh B, Hartberger JM, Frey-Jakobs S, Weidinger S, Moebus L, Franke A, Schäffer AA, Bulashevska A, Fuchs S, Ehl S, Limaye S, Arkwright PD, Briggs TA, Langley C, Bethune C, Whyte AF, Alachkar H, Nejentsev S, DiMaggio T, Nelson CG, Stone KD, Nason M, Brittain EH, Oler AJ, Veltri DP, Leahy TR, Conlon N, Poli MC, Borzutzky A, Cohen JI, Davis J, Lambert MP, Romberg N, Sullivan KE, Paris K, Freeman AF, Lucas L, Chandrakasan S, Savic S, Hambleton S, Patel SY, Jordan MB, Theos A, Lebensburger J, Atkinson TP, Torgerson TR, Chinn IK, Milner JD, Grimbacher B, Cook MC, Snow AL. Hypomorphic caspase activation and recruitment domain 11 (CARD11) mutations associated with diverse immunologic phenotypes with or without atopic disease. J Allergy Clin Immunol 2019;143:1482-1495.


Arkwright PD et al. Severity and threshold of peanut reactivity during hospital-based open oral food challenges: An international multicenter survey. Pediatr Allergy Immunol. 2018;29:754-761.
PALISADE Group of Clinical Investigators, et al. HAR101 Oral Immunotherapy for Peanut Allergy. N Engl J Med. 2018;379:1991-2001
Dorjbal B et al. Hypomorphic caspase activation and recruitment domain 11 (CARD11) mutations associated with diverse immunologic phenotypes with or without atopic disease. J Allergy Clin Immunol. 2018 Aug 28.
Arkwright PD, Sharma V, Ewing CI, Hughes SM. Home-based program of maintaining unresponsiveness in children with allergic reactions to larger amounts of peanut. Ann Allergy Asthma Immunol. 2018;120:539-540.
Rajput S, Sharma V, Hughes SM, Ewing CI, Arkwright PD. Allergy testing in predicting outcome of open food challenge to peanut. J Allergy Clin Immunol. 2018;141:457-458.